Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ADCT with free AI briefings, catalyst countdowns, and dilution alerts.

ADCT · ADC Therapeutics SA

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $1.25, 26% below $1.70, its close on the day of its Oct 13 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$189.2M Cash on Hand
28.6mo Cash Runway
5.9% Short Interest
$3.33 Analyst Target (3)
Follow ADCT by email Get an email when ADCT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ADCT, unsubscribe in one click. Privacy

📣 What ADCT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Loncastuximab Tesirine (ADCT-402)
FDA approved Apr 2021 · Zynlonta
B-cell Non Hodgkin Lymphoma Phase 2/3 · NCT05991388 Recruiting
Odronextamab B-cell Non Hodgkin Lymphoma Phase 2/3 · NCT05991388 Recruiting
Chimeric Antigen Receptor T-cells B-cell Non Hodgkin Lymphoma Phase 2/3 · NCT05991388 Recruiting
Loncastuximab tesirine 75µg/Kg Marginal Zone Lymphoma Phase 2 · NCT05296070 Recruiting
Camidanlumab Tesirine (ADCT-301) Acute Myeloid Leukemia (AML) Phase 2 · NCT04639024 Terminated
Imvotamab Non-Hodgkin Lymphoma Phase 1/2 · NCT04082936 Terminated
Loncastuximab tesirine 150 µg/Kg Marginal Zone Lymphoma Phase 2 · NCT05296070 Recruiting
Idelalisib Relapsed Follicular Lymphoma Phase 2 · NCT04699461 Terminated
Vincristine Double-Expressor Lymphoma Phase 2 · NCT05600686 Suspended
Doxorubicin Double-Expressor Lymphoma Phase 2 · NCT05600686 Suspended
Epratuzumab-cys-tesirine (ADCT-602) Blasts 5 Percent or More of Bone Marrow Nucleated Cells Phase 1/2 · NCT03698552 Terminated
Melphalan Recurrent Diffuse Large B-Cell Lymphoma Phase 1 · NCT05228249 Withdrawn
Trastuzumab/Tesirine Antibody-drug Conjugate… Breast Cancer Phase 1 · NCT03125200 Terminated
Mipasetamab Uzoptirine (ADCT-601) Advanced Solid Tumors Phase 1 · NCT05389462 Terminated
Olintatug Tesirine (ADCT-901) Advanced Solid Tumors Phase 1 · NCT04972981 Completed

Also used in these trials (approved or third-party drugs, not ADCT's own candidates): Gemcitabine Hydrochloride, Rituximab, Etoposide Phosphate, Oxaliplatin, Carboplatin, Etoposide, Ifosfamide, Dexamethasone, Prednisone, Epcoritamab, Cyclophosphamide, Ibrutinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADCT holds $189.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $19.8M/quarter from operations, an estimated runway of 28.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADCT files for a raise →

👥 Who Owns ADCT

Insiders 30.4% Other 5%+ holders 20.5% Institutions (146 holders) 49.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
Redmile Group, LLC
10% owner · +6.49M options
Insider 22,932,028 17.96% 2026-03-31
Bain Capital Life Sciences Opportunities 5%+ holder (13G) 14,825,625 11.61% 2026-10-22
Nantahala Capital Management, LLC Institution (13G, 5%+) 12,326,184 9.65% 2026-06-30
TCG Crossover GP II, LLC 5%+ holder (13G) 11,390,175 8.92% 2025-10-27
TCG Crossover Management, LLC Institution (13F) 11,390,175 8.92% 2026-09-30
Hans Peter Wild
10% owner
Insider 9,788,944 7.67% 2025-05-15
BlackRock, Inc. Institution (13G, 5%+) 6,857,815 5.37% 2026-06-30
AIGH Capital Management LLC Institution (13F) 4,324,327 3.39% 2026-09-30
Opaleye Management Inc. Institution (13F) 4,070,819 3.19% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 3,485,435 2.73% 2026-09-30
Morgan Stanley Institution (13F) 2,717,262 2.13% 2026-09-30
Citadel Advisors Llc Institution (13F) 2,446,868 1.92% 2026-09-30

Share count 127,667,695 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-06-30
filed 2026-07-02
MALLIK AMEET
Award (A) 675,000 – 2,121,769
2026-06-30
filed 2026-07-02
Zaki Mohamed
Award (A) 213,900 – 896,317
2026-06-30
filed 2026-07-02
GRAHAM PETER J
Award (A) 221,100 – 841,640
2026-06-30
filed 2026-07-02
Carmona Jose
Award (A) 203,700 – 938,076
2026-06-03
filed 2026-06-03
Monges Viviane
Tax withholding (F) 2,596 $3.08 186,447

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ADCT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADCT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.